{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Central+Nervous+System+Anomalies&page=8",
    "query": {
      "condition": "Central Nervous System Anomalies",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1707,
    "total_pages": 171,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Central+Nervous+System+Anomalies&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Central+Nervous+System+Anomalies&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T14:52:50.458Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04320940",
      "title": "Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy, Benign Neonatal"
      ],
      "interventions": [
        {
          "name": "Phenobarbital Sodium Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NEMA Research, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "34 Weeks",
        "maximum_age": "44 Weeks",
        "sex": "ALL",
        "summary": "34 Weeks to 44 Weeks"
      },
      "enrollment_count": 4,
      "start_date": "2021-03-12",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320940"
    },
    {
      "nct_id": "NCT00975689",
      "title": "Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Niemann-Pick Disease, Type C"
      ],
      "interventions": [
        {
          "name": "N-Acetyl Cysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-08",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2013-05-06",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975689"
    },
    {
      "nct_id": "NCT02612376",
      "title": "Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Down Syndrome",
        "Mild Cognitive Impairment"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2016-02",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02612376"
    },
    {
      "nct_id": "NCT03709173",
      "title": "FuRST 2.0 Cognitive Pre-testing - Round 2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "FuRST 2.0",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "CHDI Foundation, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2019-08-02",
      "completion_date": "2019-10-25",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 3,
      "location_summary": "Englewood, Colorado • Wichita, Kansas • New York, New York",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709173"
    },
    {
      "nct_id": "NCT03403205",
      "title": "Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wilson Disease"
      ],
      "interventions": [
        {
          "name": "ALXN1840",
          "type": "DRUG"
        },
        {
          "name": "SoC Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2018-02-22",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03403205"
    },
    {
      "nct_id": "NCT05194124",
      "title": "Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bardet-Biedl Syndrome",
        "POMC Deficiency"
      ],
      "interventions": [
        {
          "name": "Setmelanotide 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Setmelanotide 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Setmelanotide 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Setmelanotide 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Setmelanotide 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Setmelanotide 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhythm Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2021-12-21",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Marshfield, Wisconsin",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194124"
    },
    {
      "nct_id": "NCT05322096",
      "title": "Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prader-Willi Syndrome"
      ],
      "interventions": [
        {
          "name": "RGH-706",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gedeon Richter Plc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2022-09-22",
      "completion_date": "2024-04-10",
      "has_results": false,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Chicago, Illinois • Brooklyn, New York + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05322096"
    },
    {
      "nct_id": "NCT02352896",
      "title": "Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leigh Syndrome"
      ],
      "interventions": [
        {
          "name": "EPI-743",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-01-31",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 4,
      "location_summary": "Stanford University, California • Akron, Ohio • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Stanford University",
          "state": "California"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02352896"
    },
    {
      "nct_id": "NCT00446862",
      "title": "The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "19 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2007-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446862"
    },
    {
      "nct_id": "NCT00237627",
      "title": "Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Ovarian Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "PS-341",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        },
        {
          "name": "Velcade",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2001-05",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2012-05-18",
      "last_synced_at": "2026-10-11T14:52:50.458Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00237627"
    }
  ]
}